A detailed history of Bank Of America Corp transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 83,950 shares of ORIC stock, worth $713,575. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,950
Previous 276,489 69.64%
Holding current value
$713,575
Previous $1.95 Million 55.99%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.52 - $11.9 $1.45 Million - $2.29 Million
-192,539 Reduced 69.64%
83,950 $860,000
Q2 2024

Aug 14, 2024

BUY
$6.63 - $12.93 $499,683 - $974,495
75,367 Added 37.47%
276,489 $1.95 Million
Q1 2024

May 15, 2024

BUY
$8.04 - $16.03 $767,273 - $1.53 Million
95,432 Added 90.29%
201,122 $2.77 Million
Q4 2023

Feb 14, 2024

SELL
$5.41 - $9.43 $215,648 - $375,889
-39,861 Reduced 27.39%
105,690 $972,000
Q2 2023

Aug 14, 2023

BUY
$4.95 - $8.4 $100,554 - $170,637
20,314 Added 16.22%
145,551 $1.13 Million
Q1 2023

May 12, 2023

BUY
$4.26 - $6.75 $393,866 - $624,084
92,457 Added 282.05%
125,237 $713,000
Q4 2022

Feb 10, 2023

BUY
$2.41 - $5.89 $7,861 - $19,213
3,262 Added 11.05%
32,780 $193,000
Q3 2022

Nov 14, 2022

BUY
$3.15 - $5.24 $14,682 - $24,423
4,661 Added 18.75%
29,518 $95,000
Q2 2022

Aug 12, 2022

SELL
$2.7 - $7.07 $14,806 - $38,771
-5,484 Reduced 18.07%
24,857 $111,000
Q1 2022

May 16, 2022

SELL
$4.54 - $16.1 $215,749 - $765,104
-47,522 Reduced 61.03%
30,341 $162,000
Q4 2021

Feb 08, 2022

BUY
$12.01 - $20.3 $779,316 - $1.32 Million
64,889 Added 500.15%
77,863 $1.15 Million
Q3 2021

Nov 15, 2021

SELL
$15.9 - $25.22 $108,756 - $172,504
-6,840 Reduced 34.52%
12,974 $271,000
Q2 2021

Sep 13, 2021

BUY
$17.37 - $25.34 $344,169 - $502,086
19,814 New
19,814 $351,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $336M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.